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b2-Microglobulin (b2M), a component of MHC class I molecules, is believed to be associated with tumour status in various cancers. In
this study, we examined the expression of b2M at different malignant stages of oral cavity squamous cell carcinoma (OCSCC). To
determine the possible correlation between b2M expression and various clinical characteristics, 256 samples from patients with
OCSCC were evaluated by immunohistochemical staining. Strong b2M expression was significantly correlated with a relatively
advanced tumour stage (Po0.001), positive nodal status (Po0.001), and TNM stage (Po0.001). The cumulative 5-year survival rate
was significantly correlated with a relatively advanced tumour stage (Po0.001), positive nodal status (Po0.001), TNM stage
(Po0.001), and strong expression of b2M (Po0.001). Thus, elevated b2M expression is an indicator of poor survival (Po0.001). In
addition, we extended our analysis of b2M expression to the FaDu and SCC25 oral cancer cell lines. b2-Microglobulin expression
was positively correlated with cell migration and invasion in b2M-overexpressing transfectants in Transwell chambers. The
suppression of b2M expression using small interfering RNA (siRNA) was sufficient to decrease cell migration and invasion in vitro.
Taken together, our results suggest that b2M expression in the tissues is associated with survival and may be involved in tumour
progression and metastasis in OCSCC.
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b2-Microglobulin (b2M), an 11.7-kDa polypeptide expressed on
the surface of almost all cells in the body, forms complexes with
major histocompatibility complex (MHC) class I molecules, which
are believed to function in antigen presentation to cytotoxic
(CD8þ) T lymphocytes (Margalit et al, 2006). b2-Microglobulin is
present as a soluble protein at low levels in the serum, urine, and
other bodily fluids under physiological conditions; however, its
level is elevated in patients with kidney failure and certain
malignancies, including solid and liquid tumours (Klein et al,
1996; Tsimberidou et al, 2008). The increased tissue/serum level of
b2M is associated with a high tumour burden and poor prognosis.
Thus, the level of b2M has become one of the most important
prognostic factors and predictors of survival in patients with
certain cancers (Lee et al, 2000; Madjd et al, 2005; Tsimberidou
et al, 2008). Numerous reports, however, have indicated that a rise
in the level of b2M does not necessarily indicate a poor prognosis,
suggesting that the changes in b2M expression differ between
premalignant and malignant tumours (Mahrle et al, 1982;
Korkolopoulou et al, 1996; Feenstra et al, 2000; Palmisano et al,
2001). The first studies of cancer cells with upregulated or
downregulated b2M expression were initiated two decades ago;
however, to date, few articles have shown that a decrease in the cell
surface concentration of b2M is associated with a poor prognosis
in malignant cases of oral cavity squamous cell carcinoma
(OCSCC) (Prime et al, 1987; Feinmesser et al, 2004). Instead,
prominent staining for b2M in tumours is associated with an
improved clinical outcome. Oral cavity squamous cell carcinoma is
currently the most frequently detected head and neck cancer in
Southeast Asia. In Taiwan, OCSCC is the fifth most common
malignancy in men, although it is highly curable at an early stage
(Lu et al, 2007). The identification of biomarkers for evaluating the
progression of OCSCC is therefore urgent. The aim of this study
was to investigate the clinicopathological significance of b2M
expression according to tumour status in patients with OCSCC.
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sUsing b2M-overexpressing transfectants, we found a statistically
significant correlation between elevated b2M expression and oral
cancer cell invasion and migration.
MATERIALS AND METHODS
Patients and tumour samples
The subjects included 256 patients without previous radiotherapy
and/or chemotherapy who underwent primary surgical resection
between October 1996 and August 2005 for the treatment of
OCSCC. Clinicopathological information, including sex, age,
primary tumour stage (T), nodal status (N), and tumor-node-
metastasis (TNM) stage, was obtained from each patient’s clinical
records and pathologic reports. Tumor-node-metastasis status was
assigned according to the 1997 American Joint Committee on
Cancer staging system. Tumor-node-metastasis was defined as size
or direct extent of the primary tumour (T, 1–4) that spreads to
regional lymph nodes (N, 0–3) and develops distant metastasis
(M, 0/1). This study was approved by the Medical Ethics and
Human Clinical Trial Committee at Chang Gung Memorial
Hospital, Taiwan. The study subjects included 17 women
and 239 men with an average age of 50.9 years (range: 26–87).
Thirty-nine of the patients were classified as T1, 55 as T2, 64 as T3,
and 98 as T4. One hundred and fifty-three patients were classified
as N0, 38 as N1, 48 as N2b, 13 as N2c, and 4 as N3. Thirty-four
patients were classified as TNM stage I, 38 as stage II, 61 as stage
III, and 123 as stage IV. The mean follow-up period was 49.3
months (range: 2–141).
Antibodies and reagents
Polyclonal antibodies against human b2M and HLA class I were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Monoclonal antibodies against b-actin were obtained from Sigma
(St Louis, MO, USA). Anti-HA antibodies were purchased from
Roche Biochemicals (3F10; Indianapolis, IN, USA). Horseradish
peroxidase (HRP)-conjugated anti-rabbit IgG, HRP-conjugated
anti-mouse IgG, FITC-conjugated anti-rabbit IgG, and TRITC-
conjugated anti-mouse IgG were purchased from Jackson
ImmunoResearch laboratories (Bio/Can Scientific, Mississauga,
ON, Canada). An HRP/Fab polymer conjugate kit and DAB were
obtained from Zymed (PicTuret-Plus Kit; South San Francisco,
CA, USA). SuperScript II Reverse Transcriptase and all PCR and
cell transfection reagents were purchased from Invitrogen
(Carlsbad, CA, USA). All cell culture-related reagents were
purchased from Gibco-BRL (Grand Island, NY, USA).
RNA extraction and semiquantitative reverse
transcription-PCR
Tissue samples were frozen in liquid nitrogen and stored at  801C
before RNA extraction. The tissues were homogenised using a
Mixer Mill Homogenizer (Qiagen, Crawley, West Sussex, UK).
Total RNA was extracted from the tissue samples using an RNeasy
Mini Kit (Qiagen) according to the manufacturer’s instructions.
The total RNA (2mg) was reverse-transcribed into cDNA using
SuperScript II Reverse Transcriptase. Polymerase chain reaction
was performed using 1ml of the reverse transcription product in a
reaction volume of 25ml. The primers used were b2M forward:
50-CTCACGTCATCCAGCAGAGA-30 and reverse: 50-CGGCAGGCAT
ACTCATCTTT-30; and GAPDH forward: 50-GAAGGTGAAGGT
CGGAGTC-30 and reverse: 50-GAAGATGGTGATGGGATTTC-30.
GAPDH was used as an internal control to normalise the relative
amount of cDNA in each reaction. The number of cycles
corresponding to the logarithmic phase of amplification for b2M
was determined before the start of our experiments. The PCR
mixture contained 10mM Tris-HCl (pH 8.3), 1.5mM MgCl2,5 0m M
KCl, 200mM dNTPs, 2mM each primer, and 1U of Ex Taq
Polymerase (Takara, Tokyo, Japan). The programme included 25
cycles at 941C for 1min, 561C for 1min, and 721C for 2min. The
reverse transcription-PCR (RT–PCR) products were separated on
2% agarose gels and stained with 0.5mgml
 1 ethidium bromide.
The b2M product was 213bp long.
Immunoblot analysis
Immunoblotting was carried out according to standard proce-
dures. For tissue protein extraction, samples were frozen and
homogenised in lysis RIPA (radioimmunoprecipitation assay)
buffer (50mM Tris-HCl (pH 7.5), 150mM NaCl, 1% NP-40, 0.5%
Na-deoxycholate, and 0.1% SDS). The protein concentration in
each sample was estimated by Bio-Rad protein assay (Hercules,
CA, USA). Equal amounts of protein (50mg) were electrophoresed
on reducing 10% SDS–polyacrylamide gels and then transferred to
polyvinylidene difluoride membranes. After blocking with TBS/5%
bovine serum albumin (BSA), antibodies against b2M, HA, and
b-actin were incubated with the membranes at room temperature
for 1h. The resulting IgGs were detected using HRP-conjugated
secondary antibodies and developed using Western Lighting
reagent.
Immunohistochemistry
Normal oral mucosa and adjacent non-tumour and tumour
OCSCC tissue samples were selected by a pathologist on the basis
of diagnosis and microscopic morphology. Normal oral mucosa
and tumour tissues were fixed with 10% buffered formalin
embedded in paraffin and decalcified in 10% EDTA solution.
Representative blocks of the formalin-fixed, paraffin-embedded
tissues were cut to 4mm thickness and deparaffinised with xylene
and rehydrated in a series of ethanol washes (100, 90, 80, and
70%). Slides were washed with phosphate-buffered saline (PBS)
and treated with 3% H2O2 for 30min to block endogenous
peroxidase activity. Next, the sections were microwaved in 10mM
citrate buffer, pH 6.0, to unmask the epitopes. After antigen
retrieval, the sections were incubated with diluted anti-b2M
(1:200) or anti-HLA-I antibody (1:200) for 1h followed by
PBS wash. Horseradish peroxidase/Fab polymer conjugate
(PicTuret-Plus kit; Zymed) was then applied to the sections for
30min followed by PBS wash. Finally, the sections were incubated
with peroxidase substrate diaminobenzidine for 5min to develop
the signals. A negative control was run simultaneously by omitting
the primary antibody. To grade for the intensity of b2M
immunostaining, the level of immunoreactivity in the immuno-
stained tissues was evaluated independently by two pathologists
who were blinded to the subjects’ clinical information. To evaluate
the expression of b2M, the tissue sections were examined under a
microscope at a magnification of  200. The intensity of staining
was classified according to a four-level scale:  , no or faint
staining in a few tumour cells; þ, weak cytoplasmic staining in
most tumour cells; þþ, diffuse cytoplasmic staining in groups of
tumour cells; and þþþ, diffuse cytoplasmic staining in most of
the tumour cells (Yagasaki et al, 2003). Levels   and þ were
defined as weak b2M expression, whereas levels þþand þþþ
were defined as strong expression. A sample was considered
positive if 1–5% of the tumour cells showed positive staining as
described (Mehta et al, 2008). Those samples in which positive
staining were detected in over 50% of the tumour cells were
considered strongly positive for b2M.
Construction of the human b2M plasmid
Two primers, 50-ATGTCTCGCTCCGTGGCCTT-30 and 50-TTA-
CATGTCTCGATCCCACT-30, were used to amplify the b2M cDNA
from the SCC25, a cell line derived from OCSCC cDNA library.
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(Qiagen). Total RNA from SCC25 cells was extracted using the
RNeasy Mini kit (Qiagen) according to the manufacturer’s
instructions. Total RNA (2mg) was reverse-transcribed into cDNA
by SuperScript II reverse Transcriptase. The PCR mixture
contained 10mM Tris-HCl (pH 8.3), 1.5mM MgCl2,5 0 m M KCl,
200mM dNTP, and 2mM of each primer with 1U of Ex Taq
Polymerase (Takara). The PCR involved denaturation at 941C for
1min and reaction at 621C for 1min and 721C for 2min for a total
of 35 cycles. The purified PCR product was constructed and
sequenced. GenBank accession number for b2M is NM_004048.
The full-length b2M was subcloned into the pcDNA3.1, a HA-
tagged expression vector.
Cell culture establishment of stable clones, and transient
transfection of b2M siRNA
FaDu and SCC25 cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% heat-inactivated foetal bovine
serum (FBS) and 100Uml
 1 penicillin and streptomycin.
Transient transfection of FaDu and SCC25 cells with HA-tagged
b2M was achieved using Lipofectamine according to the manu-
facturer’s instructions. FaDu and SCC25 cells stably expressing
b2M were selected using 400mgml
 1 G418 (Calbiochem Novabio-
chem, San Diego, CA, USA). Each clone was harvested and
analysed for exogenous b2M expression by western blotting. Each
stable clone was then lysed in extraction buffer (20mM piperazine-
N,N0-bisethane sulphonic acid, pH 7.2, 100mM NaCl, 1mM EDTA,
0.1% 3-[(3-cholamido propyl)-dimethylammonio]-2-hydroxy-1-
propanesulphonic acid, 10% sucrose, 1mM DTT, 1mM PMSF,
and 1mM Na3VO4) as described earlier (Hsu et al, 2004). Double-
stranded synthetic RNA oligomers (Ambion, Austin, TX, USA)
(50-UUGCUAUGUGUCUGGGUUUtt-30 and 50-AAACCCAGACAC
AUAGCAAtt-30), deduced from human b2M, and one negative
control siRNA (50-uucaugugucugugguguutt-30 and 50-AACACCAC
AGACACAUGAAtt-30) were used in our siRNA experiments
(Nomura et al, 2006).
Flow cytometry
For analysis of the expression level of b2M and HLA-I molecule in
cancer cell surface, we used flow cytometry to perform the
experiments. FaDu cells were trypsinised and harvested in PBS.
The cells were incubated with a 1:100 dilution of anti-b2M and
anti-HLA class I (Santa Cruz Biotechnology) antibodies or an
equivalent concentration of isotype-specific mouse IgG in PBS with
1% BSA overnight at 41C with gentle agitation. After washing, cells
were incubated for 30min at room temperature with 1:500
dilution of FITC-conjugated anti-rabbit and TRITC-conjugated
anti-mouse IgG secondary antibody, then washed with PBS-1%
BSA. The cell-associated fluorescence of 10000 events per sample
was analysed in a FACScan flow cytometer (Becton Dickinson, San
Jose, CA, USA) using the Cell Quest software.
Migration and invasion assay
Migration and invasion assays using FaDu/vehicle, FaDu/b2M,
SCC25/vehicle, and SCC25/b2M stable clones were conducted
using 24-well Transwell (8-mm pore size polycarbonate membrane;
CoStar, Bethesda, MD, USA) chambers. For the migration assays,
5 10
3 cells suspended in 400ml of DMEM containing 10% FBS
were seeded onto the upper chamber, whereas 600ml of DMEM
containing 10% FBS was added to the outside of the chamber. After
24h of culture at 371C under 5% CO2/95% air, the cells on the
upper surface of the membrane were removed using a cotton tip
applicator, whereas the migratory cells on the lower membrane
surface were fixed with methanol and stained with Giemsa
(Sigma). Migration was assessed by counting the number of cells
that had migrated on three independent membranes under a phase
contrast microscope ( 200); this value was then normalised
against that for the vehicle cells to produce the relative ratio. For
the invasion assays, 117mg of Matrigel (BD Biosciences, San Jose,
CA, USA) was added to the upper surface of the membrane and
allowed to gel overnight at 371C. Matrigel is a commercial product
extracted from a mouse sarcoma rich in extracellular matrix
proteins. The major component is laminin, followed by collagen IV
and heparin sulphate proteoglycans. In total, 1 10
4 cells in 400ml
of DMEM containing 10% FBS were seeded onto the upper
chamber, whereas 600ml of DMEM containing 10% FBS was added
to the outside of the chamber. The subsequent steps were the same
as in the migration assays.
Statistical analysis
Several clinicopathological factors were evaluated, including sex,
age (p59 years versus X60 years), T stage (T1, T2 vs T3, T4),
N status, and TNM stage (stage I, II vs stage III, IV). Fisher’s exact
test was used to evaluate the correlation between the clinicopatho-
logical variables and the b2M expression level. A P-valueo0.05
was considered to be significant. The clinicopathological variables
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Figure 1 b2-Microglobulin (b2M) is overexpressed in OCSCC. (A)
RT–PCR analysis of b2M expression in OCSCC samples (T) vs that in
adjacent non-tumour tissues (N). GAPDH was used as an internal loading
control to normalise the amount of RNA. (B) Western blot analysis of
b2M expression in eight paired patients with oral cancer. Total protein
extracts were prepared from adjacent non-tumour (N) and tumour (T)
tissues and probed with polyclonal antibodies against human b2M. b-Actin
was used as a control for equal protein loading.
Expression of b2M at different malignant stages of OCSCC
C-H Chen et al
1455
British Journal of Cancer (2008) 99(9), 1453–1461 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sand b2M expression data were taken into account for the analysis
of survival based on the Kaplan–Meier method; statistical
significance was defined as a P-valueo0.05 as assessed by the
log-rank test. To determine the effect of specific prognostic factors
on survival, a multivariate analysis was performed according to
Cox’s regression model.
RESULTS
Analysis of b2M Overexpression in OCSCC
The mRNA expression of b2M was evaluated by semiquantitative
RT–PCR using a panel of paired tumour/adjacent non-tumour
tissue samples. Compared with the adjacent non-tumour tissues,
almost all of the OCSCC samples displayed elevated b2M
expression; only two of them showed downregulation of b2M
(Figure 1A). Similar results were obtained for the protein
expression of b2M (Figure 1B). The band corresponding to b2M
was detected in each of the tumour samples. The identity of the
band was confirmed by preincubating the sample extracts with
anti-b2M antibodies followed by immunoprecipitation (data not
shown). A high percentage of the OCSCC samples (seven of eight,
87.5%) showed enhanced b2M expression as compared with the
adjacent non-tumour tissues. Taken together, these data indicate
the elevated expression of b2M in OCSCC.
Association of b2M expression with various
clinicopathological features
b2-Microglobulin expression in the cytoplasm and cytoplasma
membrane of tumour epithelial cells collected at various stages
(T1, T2 and T3, T4) was compared with that in normal oral mucosa
and cells from the adjacent non-tumour tissues by immuno-
histochemistry (Figure 2A–F). The normal oral mucosa was no or
very weak intensity for b2M staining mainly in plasma membrane
(Figure 2A). Prominent staining was observed in the tumour
samples (Figure 2C–F) compared with that in the adjacent non-
tumour tissues, which showed no or very weak b2M expression
(Figure 2B). It can be noted that b2M was found largely localised in
1.1
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Figure 2 Immunohistochemical staining for b2M and overall survival in patients with OCSCC. (A–F) The b2M intensity on tissues was evaluated by
immunohistochemical staining. (A) The b2M protein was localised at plasma membrane in normal mucosa tissue. Tumour tissues with plasma membrane
(C, E) or cytoplasmic (D, F) b2M staining were classified according to a two-grade scale: absent or weak staining ( /þ C, D), and strong staining (þþ/
þþþ, E, F) as compared with weak b2M staining in adjacent non-tumour oral tissue (B). (G) The survival period for those patients (n¼184) with strong
(þþ/þþþ) tumour expression (dashed line) was significantly shorter than that for those (n¼72) with absent or weak (–/þ) expression (solid line).
The difference in survival was statistically significant (Po0.001) according to the log-rank test. Overall survival was calculated from the time of surgery to the
date of death, the event of interest, or the date of last follow-up. All statistical analyses were performed using SPSS software.
Expression of b2M at different malignant stages of OCSCC
C-H Chen et al
1456
British Journal of Cancer (2008) 99(9), 1453–1461 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sthe cytoplasm of both tumour samples (Figure 2D and F) and the
adjacent non-tumour tissues (Figure 2B). In some cases, b2M was
also expressed focally in the plasma membrane (Figure 2C and E).
Our immunohistochemical data and the correlation with various
clinicopathological variables are summarised in Table 1. Of the 94
patients categorised as T1, T2, 73.4% (n¼69) of the tumours
showed no or weak staining ( /þ), whereas only 26.6% (n¼25)
exhibited strong staining (þþ/þþþ). In contrast, of 162
patients classified as T3, T4, 1.97% (n¼3) showed a reduction in
b2M staining ( /þ), whereas 97.5% (n¼159) presented with
strong (þþ/þþþ) staining. Similarly, among the 103 patients
who were N(þ), 95.2% (n¼98) of the tumours showed strong
(þþ/þþþ) b2M expression, whereas only 4.8% (n¼5)
showed weak ( /þ) expression. In terms of TNM stage, 100%
(n¼184) showed strong staining in the more malignant stages (III,
IV), whereas 100% (n¼72) presented with weak staining at less
malignant stages (I, II). These data suggest that increased
expression of b2M is significantly correlated with a relatively
advanced tumour stage (T3, T4 vs T1, T2, Po0.001), positive nodal
status (N(þ) vs N(–), Po0.001), and TNM stage (III, IV vs I, II,
Po0.001). In contrast, no correlation was observed between b2M
expression and sex or age.
Analysis of survival according to b2M expression
The Kaplan–Meier analysis of our immunohistochemical results
for the patients with OCSCC revealed that the cumulative 5-year
overall survival rate was significantly correlated with
the clinicopathological characteristics and expression of b2M
(Table 2 and Figure 2G). The disease-free survival rates for those
patients in stages T1 and T2 with a negative nodal status and
stages I and II were significantly higher than for those in stages T3
and T4 with a positive nodal status and stages III and IV
(all Po0.001, log-rank test). Taken together, the overall survival
rates for those patients with weak b2M expression (92.4%) were
significantly higher than for those with b2M overexpression
(51.4%, Po0.001, log-rank test). These data suggest an increased
survival period for those patients with OCSCC having decreased
b2M expression.
Multivariate analysis
To determine whether b2M expression is an independent predictor
of survival, Cox’s regression analysis was carried out using tumour
stage, lymph nodal status, TNM stage, and b2M expression as
parameters. Our data indicated that tumour stage (hazard ratio
(HR): 3.293; 95% CI: 1.877–5.778; Po0.001) and nodal stage (HR:
2.990; 95% CI: 1.937–4.616; Po0.001) were each independent
prognostic factors for OCSCC (Table 3). b2-Microglobulin status
(P¼0.192) and TNM stage, however, were not independent
predictors. Although b2M was not a key independent factor in
our multivariate analysis, we suggested that b2M may play an
important role in the tumour development and nodal metastatic
processes in OCSCC patients according to the results of Tables 1
and 2.
Effect of b2M on oral cancer cell invasion and migration
To determine whether b2M expression is correlated with cellular
migration and invasion in vitro, two oral cancer cell lines, FaDu
and SCC25, were stably transfected with an expression vector
carrying human b2M cDNA or vector alone as a control. For each
cell line, two clones were selected (FaDu/b2M-1, b2M-2 and
SCC25/b2M-1, b2M-2). The level of overexpression in the FaDu/
b2M-1, b2M-2 and SCC25/b2M-1, b2M-2 cells was evaluated by
western blot analysis as shown in Figure 3A and B, left panels,
respectively. No significant difference in proliferation rate over
24h was identified between those cells carrying the vehicle control
and those cells expressing b2M by MTT assay (data not shown). In
Table 1 Clinical profile and correlation between the clinicopathological
features and intensity of b2M expression
b2M staining
Variables No. of patients Weak ( /+) Strong (++/+++) P-value
Age (years) 1
p59 202 57 145
X60 54 15 39
Gender 0.026
Male 239 63 176
Female 17 9 8
Tumor stage o0.001*
T1, T2 94 69 25
T3, T4 162 3 159
Nodal stage o0.001*
N( ) 153 67 86
N(+) 103 5 98
TNM stage o0.001*
I, II 72 72 0
III, IV 184 0 184
*Statistically significant.
Table 2 Univariate analysis of various clinicopathological features and
cumulative 5-year survival rates
Variables No. of patients
Cumulative 5-year
survival rate (%) P-value
Age (years)
%59 202 66.4 0.12
^60 54 55.1
Gender 0.14
Male 239 62.7
Female 17 81.9
Tumor stage o0.001*
T1, T2 94 84.0
T3, T4 162 52.3
Nodal stage o0.001*
N( ) 153 77.1
N(+) 103 44.7
TNM stage
I, II 72 92.4
III, IV 184 54.1 o0.001*
b2M overexpression o0.001*
Weak 72 92.4
Strong 184 54.1
*Statistically significant.
Table 3 Multivariate survival analysis
Variables Hazard ratio (95% CI) P-value
Tumor stage (T3, T4 vs T1, T2) 3.293 (1.877–5.778) o0.001*
Nodal stage (N+ vs N ) 2.990 (1.937–4.616) o0.001*
*Statistically significant.
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The ability of the b2M-expressing transfectants to migrate across
the surface of a chamber was also analysed 24h after seeding.
Compared with the vehicle-transfected FaDu cells, the migratory
ability of the FaDu/b2M-1, b2M-2 cells significantly increased by
5.5- and 6.0-fold, respectively (Po0.001, Figure 3A, middle panel).
Owing to the slightly lower level of b2M expression in SCC25 cells,
the SCC25/b2M-1, b2M-2 cells displayed 4.6- and 5.2-fold greater
migration, respectively (Po0.001, Figure 3B, middle panel). This
indicates that a rise in b2M expression is positively correlated with
the migration of FaDu and SCC25 cells. To clarify the role of b2M
in invasiveness, the ability of the transfectants to pass through
a Matrigel barrier was assayed. Compared with the vehicle-
transfected cells, the FaDu/b2M-1, b2M-2 cells showed an 8.2- and
8.8-fold greater capacity for invasion, respectively (Po0.001,
Figure 3A, right panel). Similarly, invasion by the SCC25/b2M-1,
b2M-2 increased by 7.8- and 8.0-fold, respectively (Po0.001,
Figure 3B, right panel). Taken together, these results suggest that
an increase in the level of b2M increases the in vitro migratory and
invasive capacity of FuDu and SCC25 cells. We next analysed
whether the inhibition of b2M expression would decrease the
migratory and invasive capacity of FaDu and SCC25 cells. FaDu
and SCC25 cells were transiently transfected with either si-b2M or
a negative control and two clones were selected (FaDu/si-b2M and
SCC25/si-b2M). After 24h, the cells were harvested for western
blot analysis and seeded into a Transwell apparatus for migration
and invasion assays. As shown in Figure 4A and B, left panels,
respectively, endogenous b2M expression was effectively inhibited
in the FaDu and SCC25 cells. The migratory ability of the FaDu/si-
b2M and SCC25/si-b2M cells decreased by 70 and 64% compared
to the negative controls, respectively (Po0.001, Figure 4A and B,
middle panels). The in vitro invasiveness of the two transfectants
decreased by 62 and 75% compared with the negative controls,
respectively (Po0.001, Figure 4A and B, right panels). These
results indicate that si-b2M negatively affected both the migration
and invasion of the FaDu and SCC25 cells. To address the
mechanistic basis for the activity of b2M, the expression of
membranal b2M in the transfectants was examined by flow
cytometric analysis. The representative data showed that ectopic
expression of b2M increased cell number by 3.9-fold in the
transfectants, as compared with that in the vehicle (Figure 5A). We
went on to obtain a quantitative analysis of the effect of b2M
expression on the level of HLA-1 in the transfectants. Figure 5B
showed that the expression of b2M did not significantly elevate
the level of endogenous HLA-I in the transfectants. The
immunohistochemical data further confirmed that staining
intensity for HLA-I had no significantly different between the
adjacent-non tumour and tumour tissues in b2M-overexpressing
specimens (Supplementay Figure 1).
DISCUSSION
Increased levels of b2M have been reported in solid and liquid
malignancies, and this has allowed us to investigate the role of b2M
beyond antigen presentation. This is the first study to explore
whether the level of b2M expression is an important prognostic
factor in OCSCC. Increased b2M expression was significantly
correlated with tumour stage, lymph node metastasis, and survival
(Tables 1 and 2). Our results strongly suggest that the level b2M is
a risk factor for tumour progression in OCSCC (Table 2). In
contrast to our results, reduced levels of b2M expression have been
reported in cases of head and neck squamous cell carcinoma
(HNSCC) and in malignancies of the oral mucosa, as the
downregulation of HLA expression is frequently observed in
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Figure 3 b2-Microglobulin (b2M) overexpression promotes oral cancer cell migration and invasion. (A and B, left panel) HA-tagged b2M stable clones of
FaDu and SCC25 cells were established. Cell lysates (50mg) were then prepared and subjected to immunoblot analysis with anti-HA antibodies. (A and B,
middle panel) For the migration assays, 5 10
3 cells of the FaDu/vehicle, FaDu/b2M-1 and b2M-2, SCC25/vehicle, and SCC25/b2M-1 and b2M-2 stable
clones were seeded onto the top of a Transwell insert. After 24h, the cells on the topside were scraped, and the cells that had migrated to the bottom were
fixed and stained with Giemsa. The relative-fold migration of the FaDu/vehicle, FaDu/b2M-1 and b2M-2, SCC25/vehicle, and SCC25/b2M-1 and b2M-2 cells
was normalised against the vehicle control and are presented diagrammatically. (A and B, right panel) For the invasion assays, 1 10
4 cells were seeded after
the addition of Matrigel. The relative-fold invasion of the stable clones was normalised against the vehicle cells and is shown diagrammatically. The data
represent the mean±s.d. of three independent experiments.
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smalignancies (Prime et al, 1987; Koene et al, 2004). A similar
report indicated that immunotherapy significantly restored b2M
expression and was associated with an improved outcome in
patients with HNSCC (Feinmesser et al, 2004). The experimental
group in that study was probably too small to cover all of the
tumour stages. Moreover, immunohistochemical analysis allows
for the selection of small tumour fields, but it is not representative
of the overall tumour, which may contain heterogeneous cells.
Although tumours frequently produce a variety of ‘loss’ pheno-
types (Aptsiauri et al, 2007), including defects in or the genomic
loss of the b2M locus, clinical conclusions must be drawn with
caution. To date, the mechanism responsible for an increase in
b2M expression during the progression of cancer is unclear. One
interpretation is that the level increases as a consequence of
increased cell turnover in the tumour and an enhanced immune
response to the malignant process. Another possibility is that the
tumours contain three b2M alleles instead of one. Recently,
Nomura et al (2006) demonstrated that b2M promoted growth in
human renal cell carcinomas while interrupting the b2M signalling
pathway led to apoptosis of the tumour cells. Accordingly, the
elevated expression of b2M may be associated with an increased
resistance to apoptosis. As shown in Tables 1 and 2, an increase in
the level of b2M during the progression of OCSCC is a sign of poor
prognosis. The decreased level or total loss of immunoreactive
staining for b2M may be due to the loss of the b2M locus, which
has been shown to occur in early stages of lymph node-positive
metastasising HNSCC lesions (Bockmuhl et al, 2002); mutations in
the coding region of b2M, leading to a decrease or loss of b2M
expression; or mutations in or methylation of the introns or
promoter of b2M, leading to a decrease or total loss of expression
(Feenstra et al, 1999a,b; Koene et al, 2004).
Increased expression of b2M, as detected by immuno-
histochemical staining and/or shedding of the molecule into the
urine and serum, has been observed in more advanced malig-
nancies. This suggests that b2M modulates cellular proliferation as
well as tumour cell migration and invasion. Thus, we generated
two stable clonal cell lines of oral cancer cells, FaDu and SCC25,
which overexpress b2M, and investigated whether b2M affected
cell migration and invasion in vitro. Our results revealed a positive
correlation between b2M expression and the migration and
invasion of the b2M-overexprssing transfectants (Figure 3). In
contrast, the inhibition of b2M expression by siRNA was sufficient
to reduce cellular migration and invasion in vitro (Figure 4). These
data are consistent with those showing increased immuno-
reactivity at more advanced stages of OCSCC (Figure 2 and
Table 1), suggesting that a rise in the level of b2M facilitates
tumour progression. Importantly, our immunohistochemical data
showed that very weak intensity for b2M staining of almost of all
normal oral mucosa was focally localised in the plasma membrane
compared to that mainly found in the cytoplasm of tumour
(B90 to 92%) and the adjacent non-tumour tissues (B80%).
Although cytoplasmic staining of b2M has been demonstrated in
some cases of human renal cell carcinoma (Nomura et al, 2006),
here, we highlight the changes in b2M localisation from plasma
membrane to cytoplasm between normal and tumour stages of
OCSCC. As the association of b2M overexpression was signifi-
cantly higher in those patients with OCSCC and lymph node
metastasis (Nþ) than in those without lymph node metastasis
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Figure 4 The migratory and invasive capacity of oral cancer cells is inhibited by b2M-mediated siRNA. (A and B, left panel) A negative control siRNA or
si-b2M was transfected into FaDu and SCC25 cells. After 24h, western blotting was performed using anti-b2M and anti-b-actin antibodies. (A and B, middle
and right panels) The relative-fold migration and invasion values for the FaDu/si-b2M and SCC25/si-b2M cells were normalised against the negative control
cells and are presented diagrammatically. The results represent the mean±s.d. of three independent experiments.
Expression of b2M at different malignant stages of OCSCC
C-H Chen et al
1459
British Journal of Cancer (2008) 99(9), 1453–1461 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s(N-), b2M may promote metastasis in OCSCC. Our current
findings agree with those from other reports showing that b2M
is an effective growth-promoting factor in the growth
and progression of renal cell carcinoma and prostate cancer
(Huang et al, 2006; Nomura et al, 2006). Accordingly, these
findings address the following clinical implications: (a) b2M
must play a far-reaching function than just a housekeeping gene
or the role on stabilisation and presentation of MHC class I
molecule in cells; (b) b2M may act as an effective growth-
promoting factor to facilitate tumour progression, invasion,
and migration in OCSCC; and (c) increased synthesis and/or
release of b2M by an elevated serum or urine b2M concentration
may become one of important prognostic factor and survival
predictors in OCSCC.
In conclusion, we found that b2M is aberrantly expressed in
OCSCC relative to histologically adjacent non-tumour tissue.
Moreover, b2M is an important factor for several clinicopathological
variables in OCSCC, suggesting its potential as a biomarker of the
disease. Furthermore, b2M overexpression facilitates the migration
and invasion of oral cancer cells, which supports the finding that
elevated levels of b2M are positively correlated with advanced
OCSCC. Apart from the exploration of prognostic factors in OCSCC,
our results present a potential target for immunotherapy.
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